Drugs / Tenofovir disoproxyl fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02237027 | Oct 2014 → Dec 2016 | — | CHU de Quebec-Universite Laval | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04712357 Comparator | Nov 2020 → Jan 2022 | COVID-19 | Federal University of Ceará | Unknown | No outcome recorded |
| — | NCT01479634 Comparator | Oct 2011 → Jun 2015 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir disoproxyl fumarate | “fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗2“Combination of Tenofovir disoproxyl fumarate 300mg and Emtricitabine 200 mg” NCT02237027 ↗ |
| Known as | TDF | “fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗1“Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)” NCT04712357 ↗ |
| Route | Oral | “one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗ |